Challenges in identifying and treating bipolar depression: a guide
|
|
- Thomasina Blair
- 5 years ago
- Views:
Transcription
1 Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine
2 Overview Challenges in treating bipolar disorder Costs and Impacts The Challenge of Co-Morbidities Diagnostic Challenges Challenges in treating bipolar depression Treating Bipolar Depression effectively: the evidence base Treating Bipolar Depression: Consensus Guidelines
3 Disclosures I have received grant funding from the Medical Research Council UK for a collaborative study with Janssen Research and Development LLC. Janssen Research and Development LLC are providing nonfinancial contributions to support this study. I have also received grant funding from Corcept Therapeutics Inc. I received expenses to attend conferences, and fees for lecturing and consultancy work (including attending an advisory board) from Corcept Therapeutics, Indivior, and Liva Nova.
4 CHALLENGES IN TREATING BIPOLAR DISORDER
5 Bipolar Disorder is complex Mania Subsyndromal (cyclothymia) Hypomania Substance/ alcohol abuse Mixed Maintenance Subsyndromal Depression (More chronic than this schematic suggests) Depression
6 Onset defined as the age at the first occurrence of either a manic/hypomanic or a major depressive episode. Arch Gen Psychiatry. 2007;64(5): doi: /archpsyc
7 Complexities in the diagnosis of bipolar depression Age (median), years 1. Initial diagnosis can take 10 years 2. Initial presentation typically depression 3. Symptom overlap can lead to misdiagnosis 4. One-third of patients are misdiagnosed with major depression 5. Other mental health problems are common and complicate diagnosis Judd et al 2002; Judd et al 2003; Hirschfeld et al 2003 Pini et al 2005; Krishnan 2005; Berk et al 2007; Mitchell et al 2008
8 Depressive episodes and subsyndromal symptoms predominate in bipolar disorder Patients spent approximately half their time euthymic (normal mood) Subsyndromal depressive symptoms are common Time 60 (%) Bipolar I 40 Bipolar II 20 0 ** * Time spent in different mood states: bipolar I vs bipolar II n=138; *p<0.05; **p<0.01 Joffe et al 2004
9 COSTS AND IMPACTS
10 Bipolar Disorder: Impact on society Reduced quality of life Impaired physical and social functioning Reduced employment and work productivity Carries a high suicide risk Large healthcare utilization and costs
11 What does Bipolar Disorder cost? McCrone ( ) estimated that the UK total costs for bipolar disorder and related conditions in 2007 to be 5.2 billion: 1.6 billion of which was comprised of total service costs. Total service costs included, not only health care services but also social care, criminal justice services, informal care from family members and costs associated with lost employment.
12 Quality of life measures in BD1 and BD2 patients compared to controls Mean SF-36 score ** * ** * ** * * * * * 20 0 n=253 *p<0.05 vs healthy controls p<0.05 vs healthy controls and bipolar I group n=253 *p<0.05 vs healthy controls p<0.05 vs healthy controls and bipolar I group Healthy controls Bipolar I Bipolar II Maina et al 2007 Feb;68(2):207-12
13 Illness burden and medical comorbidity in bipolar disorder (STEP-BD) Smoking More than 10 previous episodes Childhood onset Substance abuse Medical comorbidity Comorbid anxiety Prevalence of medical diagnosis: 59% Medical illness is a core feature of bipolar disorder associated with greater illness chronicity and burden STEP-BD, Systemic Treatment Enhancement Program for Bipolar Disorder Magalhães et al 2012
14 THE CHALLENGE OF CO- MORBIDITIES
15 Lifetime prevalence of co-morbid anxiety Patients (%) 100 disorders in bipolar disorder SAD Any anxiety disorder Agoraphobia b Panic disorder Panic PTSD GAD Specific attacks phobia Social phobia OCD a Includes sub-threshold bipolar disorder, bipolar I disorder and bipolar II disorder b Without panic Kessler et al 1996 Merikangas et al 2007
16 Personality Disorders comorbidity with bipolar II Vieta et al 1999 J Nerv Ment Dis. 187(4):245-8
17 High risk of addiction in bipolar disorder X % Lifetime prevalence Odds Ratio ECA study Regier et al JAMA 1990
18 Lifetime prevalence of alcohol dependence in mood disorders X Normal Unipolar MDD Bipolar 1 Bipolar 2 Schizophrenia Anxiety disorders % Alcohol dependence Odds ratio ECA study Regier et al JAMA 1990
19 Lifetime prevalence of any drug dependence in mood disorders X % Drug dependence Odds ratio Normal Unipolar MDD Bipolar 1 Bipolar 2 Schizophrenia Anxiety disorders ECA study Regier et al JAMA 1990
20 Drug misuse increases risk of suicide in Bipolar Disorder % Suicide attempts Overall Drug use disorder No drug use Dalton et al. Bipolar Disorders 2003
21 Other impacts Co-morbid substance use disorders in bipolar disorder associated with: Poorer adherence to medication (Keck et al. 1998) Poorer outcomes (Keck et al. 1998) Higher relapse rates (Tohen et al 1990) Probability of not relapsing over 4 years in 24 first episode BD patients (Tohen et al 1990)
22 DIAGNOSTIC CHALLENGES
23 Bipolar disorder is often missed in patients with major depressive episodes BRIDGE study investigated rates of undiagnosed bipolar disorder in 5,635 adults with a major depressive episode in 18 countries in Asia, Europe, and Africa and screened. Using strict DSM-IV criteria, 16% of patients fulfilled criteria for bipolar disorder: 12% met criteria for bipolar I disorder 4% for bipolar II disorder 47% of patients met DSM-IV bipolarity specifier criteria Angst et al Arch Gen Psychiatry 2011
24 Rates of bipolar symptoms in IAPTS referrals: Local data PROMPT study assessed clinical characteristics of patients referred to a South London IAPTS service 52% met criteria for current depression HOWEVER 20% met criteria for current or previous hypomania 15% met criteria for current or previous mania Hepgul et al. BMC Psychiatry (2016)
25 Why is this important?: Lack of antidepressant efficacy in Bipolar Depression Sidor & MacQueen J Clin Psychiatry 2011
26 CHALLENGES IN TREATING BIPOLAR DEPRESSION
27 Treatment Challenges in Bipolar Disorder Bipolar disorder is often unrecognised and undiagnosed Comorbidities are common and can hinder diagnosis The predominant phase is depression which can lead to misdiagnosis Long-term protection against manic and depressive symptoms The several subtypes: bipolar I and II, rapid cycling, mixed states Evans, 2000; Hirschfeld et al, 2003; Hirschfeld et al, 2003b; Judd et al, 2002; Judd et al, 2003; Citrome & Goldberg, 2005; Kupka et al, 2007.
28 Bipolar disorder: what patients would like to see most improved Better treatment of depression Less risk of weight gain Prevention of relapse in depression Improved functionality/quality of life Less risk of sleeping difficulties Less risk of suicidal thoughts Less risk of sedation Less risk of diabetes Less risk of muscle stiffness Respondents (%) Understanding Patients Needs, Interactions, Treatment, and Expectations (UNITE) Global Survey of 1300 patients with bipolar disorder McIntyre 2009
29 Treating Bipolar Depression as MDD Little evidence to support the use of antidepressant monotherapy: Antidepressant monotherapy may be ineffective (e.g. McElroy et al, 2010) No antidepressant monotherapy explicitly approved in the U.K. Risk of manic switch with antidepressant monotherapy
30 STEP-BD study STEP-BD: Large NIMH funded multicentre trial of Bipolar depression Rx 68% BPI, 32% BPII Antidepressants: n = 86 bupropion (300 mg/day) n = 93 paroxetine (30 mg/day) n = 187 placebo Sachs et al. New England Journal of Medicine 2007
31 TREATING BIPOLAR DEPRESSION EFFECTIVELY: THE EVIDENCE BASE
32 EMBOLDEN I & II Acute Phase EMBOLDEN I EMBOLDEN II Quetiapine 300 mg/day (n=265) Quetiapine 300 mg/day (n=245) Quetiapine 600 mg/day (n=268) Quetiapine 600 mg/day (n=247) Washout (5 28 days) Lithium (n=136) Washout (5 28 days) Paroxetine 20 mg/day (n=126) Placebo (n=133) Placebo (n=122) Enrolment Randomisation Acute phase (8 weeks) Enrolment Randomisation Acute phase (8 weeks) Young A et al 2010; McElroy S et al 2010
33 Improvement EMBOLDEN I & II Acute Phase EMBOLDEN I EMBOLDEN II LSM change from baseline 0 Study week Study week * *** * ** ** *** Quetiapine 600 mg (n=263) Quetiapine 300 mg (n=255) Placebo (n=129) Lithium (n=136) * ** *** *** * ** ** *** Quetiapine 600 mg (n=232) Quetiapine 300 mg (n=229) Placebo (n=121) Paroxetine (n=118) ** *** *** *** *p<0.05; **p<0.01; ***p<0.001 vs placebo; Intention to treat; last observation carried forward. Young A et al 2010; McElroy S et al 2010
34 Key points from EMBOLDEN Studies Quetiapine is effective for the treatment of bipolar depression (EMBOLDEN1&2) at both 300mg and 600mg Lithium (EMBOLDEN1) and paroxetine (EMBOLDEN2) are no better than placebo in the treatment of bipolar depression
35 Efficacy in Bipolar depression: Meta analysis Best evidence for Quetiapine (300 or 600mg) Lamotrigine results somewhat inconsistent Paroxetine and Lithium not associated with symptom improvement Olan/Flu based on single study Vieta et al. J Clin Psychopharm 2010
36 Efficacy in bipolar depression or mixed states with addiction co-morbidity Stokes et al. in preparation
37 Manic switch in bipolar disorder An antidepressant-specific switch risk: estimates vary between 6%-25%. Recent evidence for protective effect of concomitant mood stabiliser is equivocal (Bottlender et al, 2001, Tondo et al, 2010; Baldessarini et al, 2010)
38 Risk of manic switch greatest with Venlafaxine Post et al. BJPsych 2006
39 Drug and alcohol use increases risk of switching from depression to mania Ostacher (STEP-BD) Am J Psychiatry 2010
40 TREATING BIPOLAR DEPRESSION: CONSENSUS GUIDELINES
41 2014 NICE Guidelines: Treating bipolar depression Offer a high-intensity psychological intervention (CBT, IPT or couples therapy) If medication free: Offer fluoxetine & olanzapine or quetiapine If no response, stop above and treat with lamotrigine alone If already taking Lithium or Valproate: Optimise dose If no response, offer fluoxetine & olanzapine or quetiapine If no response, treat stop fluoxetine & olanzapine or quetiapine and add lamotrigine
42 BAP 2016 Consensus Guidelines: Initial treatment: Bipolar Depression Consider Quetiapine, Lurasidone or Olanzapine (all also anti-manic drugs) If no response consider antidepressants in context of mood stabilisers Fluoxetine and Olanzapine Consider initial treatment with Lamotrigine
43 BAP 2016 Consensus Guidelines: If already on treatment: Bipolar Depression Ensure adherence and adequate dosage Limited efficacy of SSRI s and potential to destabilise mood Consider tapering antidepressants when recovered
44 Conclusions Bipolar disorder is complex and depressive symptoms predominate Anxiety, PD and addictions co-mordbidity is common and impacts on treatment Bipolar depression is often missed, particuarly in bipolar II Disorder People with Bipolar disorder rank better treatments for depression as 1 st priority
45 Conclusions 2 Treatment options for bipolar depression are limited Evidence of efficacy for: Quetiapine, Lamotrigine, OFC, Lurasidone Very limited evidence base in addiction comorbidity but quetiapine may be useful 2014 NICE guidelines do not include Lurasidone unlike 2016 BAP guidelines
46 THANK YOU Dr. Paul Stokes Centre for Affective Disorders, Department of Psychological Medicine Institute of Psychiatry at King's College London Main Building, 4th floor, Room M , De Crespigny Park London SE5 8AF Tel: +44-(0)
47 QUESTIONS?
Mood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationTreatment of Bipolar disorder
8/6/215 Treatment of Bipolar disorder Pichai Ittasakul, M.D. Department of Psychiatry, Ramathibodi Hospital, Mahidol University Bipolar disorder Manic-depressive Illness. is characterized by the occurrence
More informationManagement of Bipolar Depression
Management of Bipolar Depression Haresh M. Tharwani, M.D. Associate Clinical Professor Medical Director-DRH & Duke Psychiatry Specialty Clinic of Cary, N.C. Bipolar Disorders (Manic-Depressive illness)
More informationWhat s new in the treatment of bipolar disorder?
What s new in the treatment of bipolar disorder? Dr. David Cousins MRC Clinician Scientist Institute of Neuroscience Newcastle University NCMD 2017 What s new in the treatment of bipolar disorder? Dr.
More informationBipolar Depression: Engaging the Patient. Mark Frye, MD Mayo Clinic Rochester, MN
Bipolar Depression: Engaging the Patient Mark Frye, MD Mayo Clinic Rochester, MN Mark Frye, MD Disclosures Research/Grants: AssureRX Health Inc.; Janssen Research & Development, LLC; Mayo Foundation for
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationIt's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum
It's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum Session 4022: American Psychiatric Nurses Association National Conference, Louisville, KY Andrew Penn, RN, MS, NP, CNS Psychiatric
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationBIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences BIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD PROFESSOR DEPARTMENT OF PSYCHIATRY UNIVERSITY
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationImproving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
More informationNOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression)
NOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression) 11 APRIL 2013 Josephine Cucchiaro, PhD Vice President Clinical Operations & Project Management Sunovion Pharmaceuticals
More informationPsychiatry Clinical Reviews Treating Bipolar Depression
Mayo School of Continuous Professional Development Psychiatry Clinical Reviews Treating Bipolar Depression Mark A. Frye, MD October 6-8, 2016 Intercontinental Chicago Magnificent Mile Chicago, IL 2015
More informationPDF created with pdffactory Pro trial version
با ی د ر ا ر وه روا ز ش ی دا ه ع وم ش ی ا ان Treatment Challenges in BD Major depressive episode Mixed states= 20% Rapid cycling= 18% (annually), 31.5% (lifetime) Psychiatric Comorbidity (substance abuse,
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationBipolar Disorders. Disclosure Statement. I have no financial disclosures or conflicts of interest
Bipolar Disorders Ahsan Naseem, MD Diplomate American Board of Psychiatry and Neurology Adult and Geriatric Psychiatry Medical Director Bryan Heartland Psychiatry Bryan Physician Network Partner Cheney
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More information5 COMMON QUESTIONS WHEN TREATING DEPRESSION
5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationA Critical Review of. Current Guidelines for Bipolar Disorder. R. Hamish McAllister-Williams, MD, PhD, MRCPsych
A Critical Review of Psychobiology Research Group Current Guidelines for Bipolar Disorder R. Hamish McAllister-Williams, MD, PhD, MRCPsych Reader in Clinical Psychopharmacology University of Newcastle
More informationAffective Disorders.
Affective Disorders http://www.bristol.ac.uk/medicalschool/hippocrates/psychethics/ Affective Disorders Depression Mania / Hypomania Bipolar mood disorder Recurrent depression Persistent mood disorders
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationComprehensive Pharmacologic Management of Bipolar Depression Alexander McGirr, MD, MSc 1 David J. Bond, MD, PhD 2,*
Current Treatment Options in Psychiatry (2014) 1:263 277 DOI 10.1007/s40501-014-0017-2 Mood Disorders (AH Young, Section Editor) Comprehensive Pharmacologic Management of Bipolar Depression Alexander McGirr,
More informationBipolar disorders: treatment options and patient satisfaction
REVIEW Bipolar disorders: treatment options and patient satisfaction Charles Bowden Vivek Singh Department of Psychiatry, The University of Texas Health Science Center at San Antonio, San Antonio, TX,
More informationBipolar Depression Update 2016
Bipolar Depression Update 2016 Andrew A. Nierenberg, MD Thomas P. Hackett, MD, Endowed Chair in Psychiatry Director, Bipolar Clinic and Research Program Massachusetts General Hospital Professor of Psychiatry,
More informationBipolar Disorder A Focus on Depression
clinical practice Bipolar Disorder A Focus on Depression Mark A. Frye, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies
More informationBipolar Depression Update 2015
Bipolar Depression Update 2015 Andrew A. Nierenberg, MD Thomas P. Hackett, MD, Chair in Psychiatry Director, Bipolar Clinic and Research Program Massachusetts General Hospital Professor of Psychiatry,
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationBipolar Disorder 4/6/2014. Bipolar Disorder. Symptoms of Depression. Mania. Depression
Bipolar Disorder J. H. Atkinson, M.D. Professor of Psychiatry HIV Neurobehavioral Research Programs University of California, San Diego KETHEA, Athens Slides courtesy of John Kelsoe, M.D. Bipolar Disorder
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN
UW PACC Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL
More informationSOMEWHERE OVER THE RAINBOW: RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF DEPRESSIVE MIXED STATES
SOMEWHERE OVER THE RAINBOW: RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF DEPRESSIVE MIXED STATES Learning Objectives Impart the importance of screening for the presence of mixed features and family
More informationBIPOLAR DISORDERS UPDATE. Anthony Archer, DO
BIPOLAR DISORDERS UPDATE Anthony Archer, DO OBJECTIVES Review the major developments and trends in diagnosis and management of bipolar disorders. Discuss and promote the role of the primary care physician
More informationFixing the Mix-Up Over Mixed Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Fixing the Mix-Up Over Mixed Depression Diagnosing and Treating DSM-5 Defined Mixed Features in Mood Disorders Learning Objectives
More informationMood Disorders-Major Depression
Mood Disorders Paula Gibbs, MD Assistant Professor Department of Psychiatry Medical Director of 5West Med-Psych University of Utah Hospitals and Clinics Mood Disorders-Major Depression Key Points for Major
More informationPractical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current Clinical Guidelines
SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR DISORDER Practical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current s Flavio Guzman, MD Editor Psychopharmacology Institute
More informationHow to treat depression with medication: Some rules of thumb
How to treat depression with medication: Some rules of thumb R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon. Consultant Psychiatrist Regional
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationPsychological Therapies: Effectiveness, Efficiency and Large Scale Dissemination
Psychological Therapies: Effectiveness, Efficiency and Large Scale Dissemination David M Clark University of Oxford, UK 23 rd October 2013 Outline of Talk How effective are psychological therapies? Novel
More informationObjectives. DSM-V Changes: Elimination of Multiaxial Diagnostic System
Conflicts of Interest I have no conflicts to disclose. 2014 Updates to the Updates in Pharmacotherapy Webinar Psychiatry Updates for Pharmacotherapy Specialists Jacintha S. Cauffield, Pharm.D., BCPS Associate
More informationPractice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,
Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD
More informationA systematic review of the evidence on the treatment of rapid cycling bipolar disorder
Bipolar Disorders 2013: 15: 115 137 Review Article Ó 2013 John Wiley and Sons A/S Published by Blackwell Publishing Ltd. BIPOLAR DISORDERS A systematic review of the evidence on the treatment of rapid
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationAnxiety Disorders. Fear & Anxiety. Anxiety Disorder? 26/5/2014. J. H. Atkinson, M.D. Fear. Anxiety. An anxiety disorder is present when
Anxiety s J. H. Atkinson, M.D. HIV Neurobehavioral Research Center University of California, San Diego Department of Psychiatry & Veterans Affairs Healthcare System, San Diego Materials courtesy of Dr.
More informationPharmacotherapy of Bipolar Disorder Roger S. McIntyre, MD, FRCPC
Pharmacotherapy of Bipolar Disorder Roger S. McIntyre, MD, FRCPC Professor of Psychiatry and Pharmacology University of Toronto Head, Mood Disorders Psychopharmacology Unit University Health Network Toronto,
More information#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Pediatric Bipolar Disorder: Diagnosis and Management Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston,
More informationFlorida Best Practice Medication Guidelines Principles of Practice for Adults
http://flmedicaidbh.fmhi.usf.edu Florida Best Practice Medication Guidelines Principles of Practice for Adults 1. Goal of the Guidelines Persistent gaps exist in the quality of mental health care delivered
More informationThe Challenge of Treatment in Bipolar Depression: Evidence from Clinical Guidelines, Treatment Recommendations and Complex Treatment Situations
53 The Challenge of Treatment in Bipolar Depression: Evidence from Clinical Guidelines, Treatment Recommendations and Complex Treatment Situations Authors S. Köhler 1, S. Gaus 1, T. Bschor 2, 3 Affiliations
More informationClozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders
Neuropsychobiology 2002;45(suppl 1):37 42 Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders A Case Series B. Hummel S. Dittmann A. Forsthoff N. Matzner
More informationMedication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG
Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine
More informationPediatrics Grand Rounds 5 March University of Texas Health Science Center at San Antonio I-1
Diagnosis and Treatment of Depression in Children and Adolescents Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department of Psychiatry The Disclosures
More informationCauses of Treatment Failure
Causes of Treatment Failure 1. Misdiagnosis 2. Comorbidity 3. Non diagnosed Substance Abuse 4. Non adherence to prescribed medication Presenter has no conflict of interest to disclose Is Misdiagnosis the
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationSome newer, investigational approaches to treating refractory major depression are being used.
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Depression and Anxiety Disorders Mood and anxiety disorders are common, and the mortality risk is due primarily to suicide, cardiovascular
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationAnti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of.
30-3-2007 Anti- Depressants, Mood Stabilizers: What Works Best For Bipolar Disorder? Date: March 30, 2007 Source: NIH/National Institute of. 30-3-2018 C. Psychiatric drugs: controlled trial demonstrated
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38787 holds various files of this Leiden University dissertation. Author: Koenders, Manja Title: Tangled up in mood : predicting the disease course of bipolar
More informationTreatment of Anxiety and Mood Disorders. John T. Walkup, MD Division of Child and Adolescent Psychiatry Weill Cornell Medical College New York, NY
Treatment of Anxiety and Mood Disorders John T. Walkup, MD Division of Child and Adolescent Psychiatry Weill Cornell Medical College New York, NY Disclosure: John T. Walkup, MD Consultant Advisory Board
More informationPharmacological treatment of anxiety disorders where is
Pharmacological treatment of anxiety disorders where is the room for improvement? David S Baldwin, Professor of Psychiatry BAP Masterclass, 15 th April 2011 dsb1@soton.ac.uk Declaration of interests (last
More informationPharmacotherapy of Bipolar Depression: An Update
Pharmacotherapy of Bipolar Depression: An Update Michael E. Thase, MD Corresponding author Michael E. Thase, MD University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationConcurrent Disorders
Concurrent Disorders Dr. Christy Sutherland MD CCFP dipabam Medical Director, PHS Community Services Methadone/Buprenorphine 101 Workshop April 1, 2017 Overview Introduction Epidemiology Treatment Principles
More informationKelly Godecke, MD Department of Psychiatry University of Utah
Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Best Practices in the Management of Bipolar Disorder Robert M. A. Hirschfeld, MD University of Texas Medical Branch Galveston, TX Peter
More informationDepression in Adolescents PREMA MANJUNATH, MD CHILD AND ADOLESCENT PSYCHIATRIST
Depression in Adolescents PREMA MANJUNATH, MD CHILD AND ADOLESCENT PSYCHIATRIST Francis Bacon Children sweeten labors, but they make misfortunes bitter. They increase the cares of life, but they mitigate
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationDisclosure Information
Disclosure Information I have no financial relationships to disclose. I will discuss the off label use of several depression and anxiety medications in pediatric population Pediatric Depression & Anxiety
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 4-year surveillance (2017) Bipolar disorder (2014) NICE guideline CG185 Appendix B: stakeholder consultation comments table Consultation dates: 10 to 24
More informationFor: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013
For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 This power point is only a guideline for recommendations in the treatment of psychiatric disorders. This is not comprehensive. Please
More informationPsychiatry curbside: Answers to a primary care doctor s top mental health questions
Psychiatry curbside: Answers to a primary care doctor s top mental health questions April 27, 2018 Laurel Ralston, DO Psychiatrist, Taussig Cancer Institute Objectives Review current diagnostic and prescribing
More informationLong term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment
DOI 10.1186/s40345-017-0075-7 RESEARCH Open Access Long term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment Andrei Pikalov *, Joyce Tsai, Yongcai
More informationMood Disorders for Care Coordinators
Mood Disorders for Care Coordinators David A Harrison, MD, PhD Assistant Professor, Dept of Psychiatry & Behavioral Sciences University of Washington School of Medicine Introduction 1 of 3 Mood disorders
More informationBipolar disorder. Ian M Anderson, 1 Peter M Haddad, 1 2 Jan Scott 3 4 CLINICAL REVIEW
bmj.com Visit BMJ Group s Psychiatry portal at http://www.bmj.com/specialties/psychiatry Bipolar disorder Ian M Anderson, 1 Peter M Haddad, 1 2 Jan Scott 3 4 1 Neuroscience and Psychiatry Unit, University
More informationBipolar Disorder Demystified. Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry
Bipolar Disorder Demystified Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry Underdiagnoses of Depression In Primary Care 2005 Study of 650 primary care patients on antidepressants
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationBipolar Disorders Expert Column Series Rapid-Cycling Bipolar Disorder: Emerging Treatments and Enduring Controversies
To Print: Click your browser's PRINT button. Bipolar Disorders Expert Column Series Rapid-Cycling Bipolar Disorder: Emerging Treatments and Enduring Controversies Joseph F. Goldberg, MD; Jinger Hoop, MD
More informationCNS SPECTRUMS. CME Review Article. Treatment of Bipolar Depression: Making Sensible Decisions
CNS SPECTRUMS CME Review Article Treatment of Bipolar Depression: Making Sensible Decisions This activity is sponsored by the Neuroscience Education Institute CME Information Accreditation and Credit Designation
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationApril 2016 Prepared By: Kimberly D. Griego, PharmD, CGP
April 2016 Prepared By: Kimberly D. Griego, PharmD, CGP Bipolar disorder (BD), also referred to as manic-depression, presents with dramatic swings in a person s mood and energy level, which affects their
More informationThings You Might Not Know About Psychotropic Medications But Wish You Did
Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and
More informationAdolescent depression
Diagnostic skills can differentiate 40 VOL. 1, NO. 7 / JULY 2002 teen angst from psychopathology Ann Wagner, PhD Chief, Autism and Pervasive Developmental Disorders Intervention Research Program Benedetto
More informationAging with Bipolar Disorder. Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health
Aging with Bipolar Disorder Neha Jain, MD, FAPA Assistant Professor of Psychiatry, UConn Health Objectives Define bipolar disorder in the elderly Review comorbidities How does it differ from bipolar in
More informationDecember 2014 MRC2.CORP.D.00011
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka America Pharmaceutical, Inc. advice or professional diagnosis. Users seeking
More informationIlluminating the Black Box: Antidepressants, Youth and Suicide
Illuminating the Black Box: Antidepressants, Youth and Suicide David H. Rubin, M.D. Executive Director, MGH Psychiatry Academy Director, Postgraduate Medical Education Director, Child and Adolescent Psychiatry
More informationUniversity of Groningen. Lamotrigine in bipolar depression Loos, Marcus Lambertus Maria van der
University of Groningen Lamotrigine in bipolar depression Loos, Marcus Lambertus Maria van der IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationFormulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary
More informationHHS Public Access Author manuscript Bipolar Disord. Author manuscript; available in PMC 2016 June 01.
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression Dawn F Ionescu a,b, David A Luckenbaugh c, Mark J Niciu c, Erica M Richards c, and Carlos A Zarate Jr
More information